Starbucks union plans Red Cup Day strike in 25+ cities - Bloomberg
Investing.com - Goldman Sachs initiated coverage on Keymed Biosciences Inc (HK:2162) with a Buy rating and a price target of HK$92.67, according to a research note released Monday.
Goldman Sachs analyst Honglin Yan highlighted Keymed’s status as a commercial-stage biotech company focused on immunology diseases, with its first commercialized product stapokibart recently approved in China for multiple conditions.
Stapokibart, approved in China for atopic dermatitis and chronic rhinosinusitis in the second half of 2024, and for seasonal allergic rhinitis in February 2025, is the first domestic IL-4Rα monoclonal antibody following dupilumab.
The analyst noted that stapokibart is well-positioned to provide a valuation foundation for Keymed with potential peak sales exceeding 5 billion yuan by 2035, citing its validated status and first-mover advantages for chronic rhinosinusitis and seasonal allergic rhinitis.
Goldman Sachs also expressed optimism about Keymed’s CM512 (TSLP/IL-13 BsAb) product, estimating potential global sales of $3.3 billion pre-probability of success and $694 million post-probability of success by 2035, noting it could offer a better option for asthma/COPD with potential efficacy breakthroughs and a more convenient quarterly dosage.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.